Your browser is no longer supported. Please, upgrade your browser.
AIM AIM ImmunoTech Inc. monthly Stock Chart
AIM ImmunoTech Inc.
Index- P/E- EPS (ttm)-0.44 Insider Own0.50% Shs Outstand40.69M Perf Week-6.12%
Market Cap75.99M Forward P/E- EPS next Y-0.35 Insider Trans12.56% Shs Float40.24M Perf Month-8.46%
Income-11.70M PEG- EPS next Q-0.08 Inst Own6.80% Short Float5.65% Perf Quarter-23.01%
Sales0.20M P/S379.96 EPS this Y73.20% Inst Trans45.78% Short Ratio0.98 Perf Half Y-33.81%
Book/sh1.55 P/B1.19 EPS next Y20.50% ROA-26.30% Target Price- Perf Year365.70%
Cash/sh0.96 P/C1.92 EPS next 5Y25.00% ROE-30.40% 52W Range0.38 - 7.11 Perf YTD238.24%
Dividend- P/FCF- EPS past 5Y44.30% ROI-63.20% 52W High-74.12% Beta-0.81
Dividend %- Quick Ratio50.00 Sales past 5Y-6.60% Gross Margin- 52W Low382.94% ATR0.11
Employees31 Current Ratio50.00 Sales Q/Q-41.00% Oper. Margin- RSI (14)43.38 Volatility4.45% 4.99%
OptionableNo Debt/Eq0.03 EPS Q/Q92.50% Profit Margin- Rel Volume0.36 Prev Close1.78
ShortableYes LT Debt/Eq0.03 Earnings- Payout- Avg Volume2.33M Price1.84
Recom2.00 SMA20-5.33% SMA50-12.11% SMA200-21.26% Volume829,677 Change3.37%
Nov-25-20 06:45AM  
Nov-15-20 07:01AM  
Nov-13-20 07:30AM  
Nov-02-20 09:00AM  
Oct-30-20 10:00AM  
Oct-22-20 07:30AM  
Oct-06-20 09:00AM  
Sep-22-20 06:50AM  
Sep-16-20 06:50AM  
Sep-10-20 06:50AM  
Sep-08-20 06:50AM  
Aug-31-20 05:00PM  
Aug-27-20 09:15AM  
Aug-25-20 06:55AM  
Aug-21-20 11:18AM  
Aug-17-20 09:18AM  
Aug-05-20 09:00AM  
Aug-03-20 08:00AM  
Jul-27-20 06:55AM  
Jul-09-20 06:30AM  
Jul-06-20 09:00AM  
Jun-29-20 06:55AM  
Jun-15-20 08:00AM  
Jun-11-20 09:05AM  
May-14-20 06:50AM  
Apr-29-20 06:30AM  
Apr-20-20 06:30AM  
Apr-06-20 06:30PM  
Mar-31-20 06:45AM  
Mar-26-20 08:00AM  
Mar-09-20 06:30AM  
Mar-08-20 11:34AM  
Feb-27-20 06:30AM  
Feb-18-20 06:30AM  
Feb-12-20 06:30AM  
Feb-11-20 06:30AM  
Feb-05-20 06:30AM  
Jan-16-20 05:27AM  
Dec-11-19 12:20PM  
Dec-04-19 06:30AM  
Nov-15-19 10:25AM  
Oct-23-19 06:30AM  
Oct-07-19 06:30AM  
Sep-25-19 09:50AM  
Sep-24-19 06:30AM  
Sep-19-19 08:43AM  
Sep-16-19 06:50AM  
Sep-13-19 06:50AM  
Sep-10-19 07:30AM  
Sep-09-19 07:45AM  
Sep-06-19 06:30AM  
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen, a drug of macromolecular ribonucleic acid molecule for the treatment of chronic fatigue syndrome. It is also developing Ampligen for the treatment of Hepatitis B and HIV, as well as patients with renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, urothelial, prostate, and pancreatic cancer. AIM ImmunoTech Inc. has research agreement with the Japanese National Institute of Infectious Diseases and Shionogi & Co., Ltd. to test its drug Ampligen as an adjuvant therapy for COVID-19, the new coronavirus infectious disease caused by SARS-CoV-2. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was founded in 1966 and is headquartered in Ocala, Florida.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
EQUELS THOMAS K.CEO & PresidentSep 03Buy2.0312,31625,001184,033Sep 03 10:53 AM
EQUELS THOMAS K.CEOAug 21Buy2.3310,73025,001171,717Aug 21 08:08 AM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 All Rights Reserved.